Drug Profile
Research programme: Rho kinase inhibitors - Devgen
Latest Information Update: 11 Jul 2008
Price :
$50
*
At a glance
- Originator Devgen
- Class
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Retinitis pigmentosa
Most Recent Events
- 29 Nov 2005 Preclinical trials in Eye disorders in Belgium (unspecified route)